Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Simon Prampart"'
Autor:
Simon Prampart, Sylvain Le Gentil, Marie Laure Bureau, Claire Macchi, Caroline Leroux, Guillaume Chapelet, Laure de Decker, Agnes Rouaud, Anne Sophie Boureau
Publikováno v:
BMC Geriatrics, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Aging is one of the most important prognostic factors increasing the risk of clinical severity and mortality of COVID-19 infection. However, among patients over 75 years, little is known about post-acute functional decline. Object
Externí odkaz:
https://doaj.org/article/08f3b671163045559a2856b6ced2effd
Autor:
Frederick J. Raal, Geesje Dallinga-Thie, Livia Pisciotta, Maurizio Averna, Jorge Peter, Maxime Passard, Dirk J. Blom, Barbara Sjouke, Kees Hovingh, Alexis Guedon, Maria Laura Cossu, Aurélie Thedrez, Milco Ciccarese, Raul D. Santos, Mickael Croyal, Angelo B. Cefalù, Simon Prampart-Fauvet, Gilles Lambert, Paolo Pintus
Publikováno v:
Arteriosclerosis, Thrombosis, and Vascular Biology
Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2016, 36 (8), pp.1647-1650. ⟨10.1161/ATVBAHA.116.307493⟩
Arteriosclerosis, thrombosis, and vascular biology, 36(8), 1647-1650. Lippincott Williams and Wilkins
Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2016, 36 (8), pp.1647-1650. ⟨10.1161/ATVBAHA.116.307493⟩
Arteriosclerosis, thrombosis, and vascular biology, 36(8), 1647-1650. Lippincott Williams and Wilkins
Objective— Proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors lower low-density lipoprotein (LDL) cholesterol in the vast majority of patients with autosomal dominant familial hypercholesterolemia. Will PCSK9 inhibition with monoclona